Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$310.10K$310.10K−12.4% vs Q1 2022 Net Income-$19.78M-$19.78MN/M vs Q1 2022 EPS, diluted—
Operating Income-$19,773,100N/M Operating Cash Flow-$15,968,300N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,143,400N/M Margins · derivedOperating margin-6376.4%−4188.8 pt vs Q1 2022
Net margin-6377.4%−4190.3 pt vs Q1 2022
ended Jun 30, 2022 · filed Aug 11, 2022 · 42 d after period end